MD, PhD, MBA
Desmond Thio joined the Apollo Medical Optics team in 2015 and is the Chairman of the company. He was formerly President of Philips Healthcare Greater China, in charge of strategic planning, business development and overall management of Philips Healthcare in Greater China.
Desmond’s past positions include President and COO of Pagoda Pharma Group, China, Country General Manager for Becton Dickinson, China and Hong Kong, General Manager, Oncology, Neonatology for Abbott International, USA, and Senior Director, North America Oncology Marketing, Pfizer/ Pharmacia USA.
Desmond Thio holds a degree in Electrical Engineering and a B.Sc. in Mathematics from Dalhousie University. In 1986 he received his Doctorate in Medicine from Mundial University. He also holds an M.Sc. degree in Preventive Medicine from Ohio State University and an MBA from University of South Australia. He recently received his Ph.D./DBA from University Versailles/INSEEC in Applied Economics with a focus on China’s private healthcare system.
Peter is currently hold a position as CEO for Holling Bio-pharma Corp.
Prior to joining Holling, Peter spent more than 20 years in high level management positions with global big pharma, including Pharmacia/Pfizer and Merck/Schering Plough, working as CEO or Managing Director for China and Taiwan operations.
Peter is actively involved in many bio-pharma industry associations in Taiwan and China. He is currently serving as Honorable Chairman of Taiwan Pharmaceutical Marketing and Management Association (TPMMA), and has been standing director and supervisor for the IRPMA in Taiwan and RDPAC in China.
Peter is also widely sought after as a bio-industry consultant and serves on the board of directors at Bio companies including Amcad and Phytohealth. He has a rich history of collaboration with global teams leading bio-pharma manufacturers in the areas of Business Development and Licensing, pipeline and portfolio management, and new product launches.
Mr. Wang has served as a Senior Vice President at Harbinger Venture Management since August 2000. With more than a decade of venture investment experience, Mr. Wang has been involved in three key areas for Harbinger. From 2001 to 2002, he worked for the Harbinger US office (Fremont , CA), focusing on IC design before moving to Harbinger’s Shanghai office from 2005 to 2008 to develop the Chinese domestic market. Since 2008, he has been assigned to the Harbinger Taiwan office, working in the fields of IT and Biotech.
From September 1994 to July 2000, Mr. Wang worked for MIC/III, a prestigious IT market research institute in Taiwan and the Asia-Pacific region. Prior to MIC/III, Mr. Wang was involved in professional training in IT, curriculum development, and wireless communication product manufacturing, testing, and trouble shooting.
Mr. Wang received his M.S.E.E. degree from National Taiwan University and B.S.E.E. degree from National Taiwan University of Science and Technology. He also completed the Technology Management Program (MBA-equivalent), sponsored by the Graduate School of Business Administration of National Cheng Chi University, Taiwan.
David Ma co-founded Apollo Medical Optics in 2014, and has served as Chief Operating Officer since then. David is responsible for establishing and executing corporate systems, business development, international collaboration, and the overall management of AMO. David’s prior positions include Manager of the Biotechnology Incubation Center at Academia Sinica, and Director of Business Development for Medigen Biotechnology Corp. David received his B.Sc. degree in Biochemistry from Purdue University (West Lafayette), and, in 2009, he obtained a Ph.D. in Developmental Biology from the Division of Biology and Biomedical Sciences at Washington University in St. Louis.
Allen joined Taiwan Global Biofund/ YFY Biotech Management Co. in 2007 and brought success to TGB through investment in and incubation of several biotech companies. The most successful of his portfolio companies are Taiwan Liposome Company (4152) and TaiMed Biologics (4147), both of which are IPO companies in Taiwan. He also won a licensing deal from the University of Washington and incubated an IVD company in Taiwan. He now serves as director of business development for this new company (MiCareo, Inc.). MiCareo is focused on the development of rare cell detection platforms, such as sensing circulating tumor cell prognosis and prenatal diagnosis.
He received his MBA degree from National Cheng-Chi University and holds a M.Sc. degree from Chang-Gung University.
Donald Hwang is Senior Vice President and Deputy COO of Wistron Corporation. Wistron is among the world’s largest makers of Information and Communication Technology products, including PCs, smartphones, servers & storage, industrial PCs, monitors, TVs and digital home products.
Donald has had over 30 years of industry experience since receiving his M.S.E.E. degree from Taiwan’s National Chiao-Tung University in 1983. He joined Acer as an ASIC designer in 1986, and developed Acer’s first laptop PC in 1990.
Donald has many patents under his belt and won the Taiwan National Invention Award in 1993. In 2000, he was honored with the prestigious Chinese Management Excellence Award (renamed the Taiwan National Management Excellence Award) for his outstanding contribution in R&D management.
Chan Yu Lee
Mr. Lee is a representative of Chang Xiang Investment Company, Ltd. Mr. Lee has over 10 years of experience in the financial industry and he is also highly experienced in Financial and Actuarial Engineering.
Mr. Lee holds a Master’s degree in Actuarial Science from the University of Iowa.
Andrew graduated with a Master’s degree in Public Finance from National Taipei University, and is a qualified teacher of business operations at secondary schools.
Andrew began his career in the tax, accounting, and financial departments of a listed company in Taiwan in 2006. He is currently responsible for monitoring the business of subsidiaries in financial control and accounting as well as being in charge of managing the operation of the Board for subsidiaries.